Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Corey Obrien

Pulmonary Disease Lansing, MI Doctor of Osteopathy

NPI 1437321213 CMS profile 337946

1200 E Michigan Ave, Suite 415, Lansing, MI 48912

Open in the dashboard

General payments

$14,659

462 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Corey Obrien of Lansing, MI is reported in the CMS Open Payments database as having received $14,659 across 462 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,774 99
2024 General $4,325 68
2023 General $4,475 72
2022 General $1,376 72
2021 General $1,160 71
2020 General $965 49
2019 General $584 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Corey Obrien
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Corey Obrien were reported at $1,774. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Corey Obrien Pulmonary Disease median Middle half National median
2019 $584 $377 $109–$1,340 $163
2020 $965 $230 $56–$907 $114
2021 $1,160 $269 $68–$1,072 $132
2022 $1,376 $390 $100–$1,457 $149
2023 $4,475 $419 $114–$1,659 $160
2024 $4,325 $476 $123–$1,818 $164
2025 $1,774 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $6,017 3 payments
  2. AstraZeneca Pharmaceuticals LP $1,867 95 payments
  3. Grifols USA, LLC $1,240 69 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,120 55 payments
  5. GlaxoSmithKline, LLC. $846 57 payments
  6. Regeneron Healthcare Solutions, Inc. $573 29 payments
  7. Genzyme Corporation $567 34 payments
  8. Mylan Specialty L.P. $381 19 payments
  9. Insmed, Inc. $366 25 payments
  10. Jazz Pharmaceuticals Inc. $235 10 payments
  11. Other $1,446 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,276 455 payments
  2. Education $6,258 6 payments
  3. Consulting Fee $125 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,017 2 payments
  2. ION $3,000 1 payment
  3. Prolastin-C Liquid $1,222 68 payments
  4. FASENRA $853 34 payments
  5. OFEV $758 34 payments
  6. TEZSPIRE $612 24 payments
  7. DUPIXENT $553 33 payments
  8. SPIRIVA RESPIMAT $424 20 payments
  9. BREZTRI $423 12 payments
  10. TRELEGY ELLIPTA $399 29 payments
  11. Other $5,193 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,239

Median for Internal Medicine: 777

Drug cost

$1,802,017

Median for Internal Medicine: $73,373

Branded share of claims

78.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 64 $855,439
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 194 $192,829
Xolair Omalizumab Brand 40 $163,899
Aralast Np Alpha-1-Proteinase Inhibitor Brand 11 $119,388
Nucala Mepolizumab Brand 24 $88,218
Dupixent Syringe Dupilumab Brand 23 $82,879
Dupixent Pen Dupilumab Brand 13 $59,227
Breo Ellipta Fluticasone/Vilanterol Brand 90 $46,533
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 50 $35,043
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 36 $31,563

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$52,483

Medicare's payments for the services billed

Medicare patients

401

Average age 72

Services billed

1,146

228 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 56%
Arthritis 56%
Depression 39%
Diabetes 38%
Ischemic heart disease 37%
Heart failure 36%
Chronic kidney disease 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $183
$183 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $158
$158 — —
DUPIXENT
  • GENZYME CORPORATION $145
$145 36 —
Prolastin-C Liquid
  • Grifols USA, LLC $130
$130 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

462 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record